Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTI-003: eftilagimod alpha plus pembrolizumab in first-line unresectable recurrent or metastatic HNSCC
2024-510762-16-00Phase 2Completed
- Sponsor
- Immutep Limited
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing eftilagimod alpha plus pembrolizumab with pembrolizumab monotherapy (2 arms). Primary endpoint: Objective response rate (ORR) according to RECIST 1.1. Started Nov 2021; status: completed.
02
Drugs
pembrolizumabeftilagimod alpha
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-510762-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510762-16-00.